Voorbeelden van het gebruik van P-gp in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Induction of P-gp.
P-gp inhibition by daclatasvir.
Inducers of P-gp St.
P-gp substrates or weak inhibitors.
Induction of P-gp and CYPs.
Inhibitors of CYP3A4 and P-gp.
P-glycoprotein(P-gp) interactions.
Inhibition of intestinal P-gp.
Therefore, apixaban does not inhibit P-gp mediated substrate transport.
CYP2D6 inhibition and/or P-gp.
Posaconazole also inhibits P-gp to some extent but has not been clinically studied.
Nintedanib is a substrate of P-gp.
The effects of P-gp and BCRP inducers and inhibitors on vemurafenib exposure are unknown.
Ranolazine is a substrate for P-gp.
Therefore, concomitant treatment with other P-gp substrates could lead to enhanced toxicity.
Netupitant is not a substrate for P-gp.
Medicinal products transported by P-gp in the intestine.
Cobimetinib is a substrate of P-glycoprotein P-gp.
and/or P-gp may therefore increase dolutegravir plasma concentration.
Apixaban is not a significant inhibitor of P-gp.
CYP3A, P-gp or CYP2C9 substrates.
The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-gp.
Idebenone is not a substrate for p-gp in vitro.
Ketoconazole is a potent inhibitor of CYP3A4 and P-gp.
Pazopanib is a substrate for CYP3A4, P-gp and BCRP.
Dabigatran etexilate is a substrate for the efflux transporter P-gp.
Idelalisib and GS-563117 are substrates of P-gp and BCRP.
Other medicinal products affecting P-gp.
Bedaquiline and M2 were not substrates of P-gp in vitro.
However, CYP3A4 inhibitors often also affect P-gp.